Post on 12-Oct-2020
Meet Senior Decision Makers
500 senior attendees from leading pharmaceutical, biopharmaceutical,
academics, CRO and solution provider companies will be attending. Meet
Senior VPs, Directors, & Managers with the following job titles:
Discover New Solutions
Formal and informal meeting opportunities offer delegates the
chance to discuss key solutions with leading service providers.
Services to be discussed include:
Day 3: Oligonucleotide Therapeutics & Manufacturing
• Evaluating oligonucleotides as personalised medicines
• Therapeutic antisense oligonucleotides
• Addressing CMC considerations for oligonucleotides
• Process Analytical Technologies
• Toxicology testing for oligos
• Quality assurance
• Case studies from the areas of:
o Oncology
o Genetic disorders
o Cardiovascular diseases
Day 2 Stream 1: Peptide Design, Synthesis, Analytical
Technologies
• Computer-aided design
• Overcoming the challenges in peptide aggregation
• Analytical and bioanalytical strategies for peptide
development
• Early peptide analytics and characterization
• Novel strategies for improving peptide properties: stability
and half-life extension
• Peptide screening
Day 2 Stream 2: Peptide Purification, Manufacturing & Process
Development
• Advances in manufacturing technologies for peptides
• New approaches to manufacture therapeutic peptides
• Regulatory strategies to manufacture peptides on a
commercial scale
• Recent advancements in the processes of manufacturing
peptides
• Advances in the HPLC purification of peptides
•
Day 3 Stream 1: Peptide Therapeutics:
Peptide Therapeutics Case Studies, Immunogenicity & Novel
Disease Treatments
• Therapeutics case studies from the areas of:
o Metabolic disorders:
➢ Obesity
➢ Diabetes
➢ Osteoporosis
o Endocrinology
o Immunology
o Oncology
o Infectious diseases
• Improving the immunogenicity of peptides
• New peptides for novel disease treatments: case studies
• Antimicrobials
Peptide Screening
Peptide Formulation
Peptide Characterisation
Oligonucleotides
Oligo Synthesis
Oligo Characterisation
Peptide Synthesis
Peptide Array Technologies
Display Technologies
Oligo Synthesis
Oligo Design Tools
Therapeutics Development
OLIGONUCLEOTIDE-FOCUSED STREAMS:
Day 2: Oligonucleotide Synthesis, Chemistry, Formulation &
Delivery, Process & Analytical Development
• Advanced synthesis technologies for oligos
• Oral delivery of oligos – overcoming key challenges
• Improving the potency of oligos
• Purification technology development:
o Freeze-drying
o Chromatography
• Impurity analysis
• Designing antisense oligos
• Making stable & quality oligos
PEPTIDE-FOCUSED STREAMS:
Day 1: Kick-Off Session – Turning Challenges to Successes in
Peptide Delivery and Formulation
• Oral delivery of peptides
• Novel formulation strategies for peptides
• Novel peptide delivery strategies
• Enhancing peptide bioavailability
• Updates in stability of peptide therapeutics
• Developing stable peptide formulations
• Peptide display technologies
The event form part of our successful Biologics Series; co-
located with the 13th Annual Proteins & Antibodies Congress
and 2nd Annual Bispecifics in Discovery & Development
Congress.
2020 Speakers Include:
Nigel Richardson Jennifer Franklin Rami Hannoush
McLean Pharma IONIS Pharmaceuticals Genentech
2020 Peptides Confirmed Speakers:
• Thomas Vorherr, Director Peptide Discovery, Novartis
• Michael Agrez, Chief Executive Officer, InterK Peptide Therapeutics
• David Earp, President and Chief Executive Officer, Circle Pharma
• Ali Tavassoli, Founder and Chief Scientific Officer, Curve Therapeutics
• Olivier Kitten, Founder and Chief Executive Officer, Affilogic
• Alex Batchelor, Chief Executive Officer, Orbit Discovery
• Graham Ogg, Founder, Orbit Discovery
• Andrew Young, Chief Scientific Officer, Intarcia Therapeutics
• Laura Itzhaki, Chief Scientific Officer, PolyProx Therapeutics
• Fabrizio Badalassi, Director Chemical Development, Ferring Pharmaceuticals
• Maria Van Dongen, Head of External Innovation, Discovery Sciences, Janssen
• Mathias Schaffrath, Group Head Purification, Sanofi
• Rami Hannoush, Principal Scientist, Genentech
• Jesper Soendergaard Marino, Principal Scientist, Novo Nordisk
• Andreas Hoijer, New Modality Formulation Team Leader, AstraZeneca
• Linda Thunberg, Associate Principal Scientist, AstraZeneca
• Silvia Sonzini, Senior Scientist, AstraZeneca
• Li Li, Principal Scientist, Merck
• Justin Murray, Principal Scientist, Amgen
• Sunay Chankeshwara, Associate Principal Scientist, Senior Expert Peptide Chemistry, AstraZeneca
• Martin Kenworthy, Associate Principal Scientist, AstraZeneca
• Ramesh Kumar, Scientist, Formulation and Drug Product Process Development, MedImmune
• Helen Harrison, Group Leader, Bicycle Therapeutics
• Gemma Mudd, Senior Scientist, Bicycle Therapeutics
• Jette Boll, Senior Scientist, Ferring
• Francesca Macchi, Scientist, Zealand Pharma
• Albert Isidro Llobet, Associate Fellow and Investigator, GlaxoSmithKline
• Victor Terrier, Scientist, Aelin Therapeutics
• Mark Howarth, Professor, University of Oxford
• Aline Miller, Professor, University of Manchester
• Steven Ballet, Professor, Departments of Chemistry and Bio-Engineering Sciences, Free University Brussels
• Derek MacMillan, Reader in Organic Chemistry, University College London
• Andre Cobb, Senior Lecturer in Organic Chemistry, King’s College London
2020 Oligonucleotides Confirmed Speakers:
• Gene Liau, Executive Vice President and Head, Research & Preclinical Development, Stoke Therapeutics
• Ekkehard Leberer, Senior Director, Sanofi
• Matthew Catley, Research Director, MiNA Therapeutics
• Jennifer Franklin, Director, CMC Regulatory Affairs, IONIS Pharmaceuticals
• Annekathrin Haberland, Director, Regulatory Affairs, Berlin Cures
• Nigel Richardson, Head, McLean Pharma
• Michael Keller, Senior Principal Scientist, Pre-Clinical CMC, F. Hoffmann - La Roche
• David Tew, Project Leader and GSK Senior Fellow, GlaxoSmithKline
• Konrad Bleicher, Group Leader, RNA Therapeutics, F.Hoffmann – La Roche
• Nadim Akhtar, Principal Scientist Characterisation & Control Strategy, AstraZeneca
• Hong Jiang, Scientist, Biogen
• Nagy Habib, Professor and Head of the Surgery Hammersmith Campus, Imperial College London
• Jesper Wengel, Professor of Nucleic Acid Center, University of Southern Denmark
• Andre Gerber, Professor of RNA Biology, University of Surrey
• Frank Sobott, Chair in Biomolecular Mass Spectrometry, University of Leeds
• Andrew Livingston, Professor of Chemical Engineering, Queen Mary, University of London
• Afaf El-Sagheer, Professor, University of Oxford
• Haiyan Zhou, Principal Investigator and Group Leader, University College London
• David Williams, Reader in Chemical Biology, University of Sheffield
2020 Biologics Series UK Sponsors:
Platinum Sponsors:
Gold Sponsors:
Benefits to Attending
✓ Hear from and meet with the key innovators in the peptide & oligonucleotide field. Previous attendees included:
Senior Vice President, Ferring Pharmaceuticals; Senior Director, Johnson & Johnson; Director, Novo Nordisk
✓ Discover collaborative solutions to peptide formulation and delivery. Join the kick-off sessions and discuss novel
peptide delivery strategies, oral delivery of peptide-based therapeutics and developing stable peptide formulations
✓ Discuss the latest innovations in peptide synthesis and analytical technologies. Presentations will delve into
oligonucleotide synthesis, advances in HPLC peptide purification, and computer-aided design
✓ New to 2020! Learn more about oligonucleotide synthesis, chemistry, formulation & delivery. Presentations will tap into
advanced synthesis technologies for oligos, improving their potency and addressing the key challenges in their oral
delivery
✓ New to 2020! Gain a comprehensive understanding of oligonucleotide therapeutics & manufacturing. Hear about CMC
considerations for oligos as well as case studies from therapeutic areas such as oncology and infectious diseases
✓ A high-quality programme devised with the help of our esteemed advisory board. Presentations will cover oral
delivery of peptide-based therapeutics, synthesis of oligonucleotides, therapeutic peptide manufacturing
Silver Sponsors:
Bronze Sponsors:
Networking and Programme Sponsors:
7th Annual Peptides & Oligonucleotides Congress
Day One – 27 April 2020
7th Annual Peptides & Oligonucleotides Congress
08.00 – 08.30 Registration
08.30 – 11.30 Workshop led by:
Chemical Computing Group
11.00 – 11.30 Registration & Welcome Refreshments
Kick-Off Session – Turning Challenges To Successes In Peptide Delivery and Formulation
• Oral delivery of peptides
• Novel formulation strategies for peptides
• Novel peptide delivery strategies
• Updates in stability of peptide therapeutics
• Developing stable peptide formulations
11.30 – 12.00 Kick Off Session Keynote:
The Obstacles That Bioavailability Represents To Peptide Formulation
Andreas Hoijer, New Modality Formulation Team Leader, AstraZeneca
12.00 – 12.30 Roundtable Discussion
12.30 – 13.15 Lunch
13.15 – 13.45 Designing Peptides For The Medici Drug Delivery System: Integration Of Drug-Device Design
• Attributes and constraints of Intarcia’s mini-osmotic pump
• Strategies for maximizing therapeutic effects, and minimizing adverse effects
Andrew Young, Chief Scientific Officer, Intarcia Therapeutics
13.45 – 14.15 Sponsor Presentation
14.15 – 14.45 Panel Discussion
14.45 – 15.15 The Impact Of Metabolism On Oral Bioavailability Of Peptides
In the first instance, strategies aiming at peptide modifications to maintain or to enhance solubility, while enabling permeability and good exposure upon oral administration are
discussed. The presentation then focuses on our latest insights with respect to metabolism of cyclic peptides, and how hot spots are resolved to achieve excellent oral
bioavailability. In this context, analyses of metabolites, the validation of metabolically stable isosteres for Leu and Pro, and their effect on exposure and oral uptake in rats are
reported.
Thomas Vorherr, Director Peptide Discovery, Novartis
15.15 – 15.45 Developability And Preformulation Of Peptides
Jette Boll, Senior Scientist, Ferring
7th Annual Peptides & Oligonucleotides Congress
Day One – 27 April 2020
15.45 – 16.00 Refreshments
16.00 – 16.10 Oxford Global’s Welcome Address
16.10 – 17.10 Welcome Keynote: Biologics Discovery At AstraZeneca
Three case studies will be presented describing different aspects of drug discovery. The first will describe the affinity maturation of an antibody that blocks enzyme function and
compares the co-crystal of the lead mAb with that of the affinity matured variant. The second will describe the challenges relating to intracellular delivery of biologics and how
they can be overcome, and the final case study will illustrate the use of machine learning in antibody discovery.
Tristan Vaughan, Vice President R&D, Antibody Discovery & Protein Engineering, AstraZeneca
17.10 – 18.10 Drinks Reception
7th Annual Peptides & Oligonucleotides Congress
Day Two – 28 April 2020
7th Annual Peptides & Oligonucleotides Congress
07.30 – 08.20 Registration
08.20 – 08.30 Chairperson’s Welcome Address
Peptide Design, Synthesis & Analytical Technologies
Peptide Purification, Manufacturing & Process
Development
Oligonucleotide Synthesis, Chemistry, Formulation
& Delivery, Process & Analytical Development
08.30 – 09.00 Stream Keynote Address:
Designing Peptide Inhibitors Of E3 Ubiquitin Ligases
I will present our work on peptides designed to inhibit two E3s,
SCF(Skp2) and ACP/C(Cdc20), which are key regulators of the cell
cycle and cell proliferation and important therapeutic targets. The
proteins from which they are derived adopt extended, non-helical
bioactive conformations, presenting challenges for the rational
design of chemical constraints. We have taken a number of
different approaches to overcome these challenges that can be
straightforwardly applied in both biology- and chemistry-focused
labs. I will also discuss how we are exploiting our findings and
methodologies for targeted protein degradation.
Laura Itzhaki, Chief Scientific Officer, PolyProx
Therapeutics
Stream Keynote Address:
Automated Approaches To Peptide Pre-Formulation
And Biophysics
Jesper Soendegaard Marino, Principal Scientist, Novo
Nordisk
Stream Keynote Address:
Regulatory Agency Questions And Learnings From
Recent Commercial Submissions
Jennifer Franklin, Director, CMC Regulatory Affairs,
IONIS Pharmaceuticals
09.00 – 09.30 Platforms For The Generation And High-Throughput
Screening Of Cyclic Libraries
• High-throughput screening of genetically encoded SICLOPPS
cyclic peptide libraries in cells
• Development of cyclic peptide hits into orally bioavailable
small molecules
• A microfluidics platform for generation and screening of
SICLOPPS cyclic peptide libraries
Ali Tavassoli, Founder and Chief Scientific Officer, Curve
Therapeutics
High Throughput Purification Of Synthetic Peptides
• Purification in 100mg to 1g scale for R&D
• Use of reversed phase chromatography
• High degree of automation and digital workflow from
analysis to freeze-drying
Mathias Schaffrath, Group Head Purification, Sanofi
Disruptive Delivery Technologies Of Antisense
Locked Nucleic Acids
Michael Keller, Senior Principal Scientist, Pre-Clinical
CMC, F. Hoffmann - La Roche
09.30 – 10.00 Solution Provider Presentation
Solution Provider Presentation
For sponsorship opportunities please contact
sponsorship@oxfordglobal.co.uk
Solution Provider Presentation
For sponsorship opportunities please contact
sponsorship@oxfordglobal.co.uk
10.00 – 11.20 Morning Coffee & Refreshments, One to One Meetings x3, Poster Presentation Sessions
7th Annual Peptides & Oligonucleotides Congress
Day Two – 28 April 2020
Peptide Design, Synthesis, Analytical Technologies Peptide Purification, Manufacturing & Process
Development
Oligonucleotide Synthesis, Chemistry, Formulation
& Delivery, Process & Analytical Development
11.20 – 11.50 Challenges In Peptide Analytics
Silvia Sonzini, Senior Scientist, AstraZeneca
Title To Be Confirmed
Alex Batchelor, Chief Executive Officer, Orbit
Discovery
Complete Enzyme Catalysed Oligonucleotide
Synthesis: From Single Nucleotides To Final Product
• Short oligonucleotides are synthesised from simple
nucleotide based starting materials using enzymes by
sequential addition of nucleotides
• The short oligonucleotides thus obtained are
subsequently assembled in a single templated
convergent step
• Template and product are separated using
nanofiltration to produce a high purity final product
resulting in the elimination of all chromatography
throughout the process
David Tew, Project Leader and GSK Senior Fellow,
GlaxoSmtihKline
11.50 – 12.20 Solution Provider Presentation
Disulfide-Rich Peptide Production At AmbioPharm Inc.
• Overview of complex disulfide peptides in the
marketplace
• Synthesis Methods for Peptides containing 1,2,3 & 4
Disulfide Bonds
• Case Studies of 4 different commercial production
campaigns for disulfide-rich peptides
• Short Introduction to Ambiopharm Business Operations
Mike Pennington, Chief Scientific Officer,
AmbioPharm Inc.
Solution Provider Presentation
For sponsorship opportunities please contact
sponsorship@oxfordglobal.co.uk
12.20 – 12.35
Solution Provider Presentation
Solution Provider Presentation
Solution Provider Presentation
For sponsorship opportunities please contact
sponsorship@oxfordglobal.co.uk
12.35 – 12.50 Solution Provider Presentation
For sponsorship opportunities please contact
sponsorship@oxfordglobal.co.uk
12.50 – 13.50 Lunch, Poster Presentation Sessions
7th Annual Peptides & Oligonucleotides Congress
Day Two – 28 April 2020
Peptide Design, Synthesis, Analytical Technologies Peptide Purification, Manufacturing & Process
Development
Oligonucleotide Synthesis, Chemistry, Formulation
& Delivery, Process & Analytical Development
13.50 – 14.20 Overcoming The Challenges In Peptide Aggregation
Francesca Macchi, Scientist, Zealand Pharma
Impact of Trace Level Impurities in Formulation
Excipients on to the Stability of Drug Product
Ramesh Kumar, Scientist, Formulation and Drug
Product Process Development, MedImmune
Risk-based Analytical Control Strategy For Antisense
Oligonucleotides Therapeutics
A phase appropriate and risk-based control strategy was
implemented at Biogen to support a portfolio of ASOs from
the start of clinical development to market distribution.
Due to structural similarities among the ASO molecules,
platform analytical methods are applied as much as
possible. Prior knowledge is leveraged to allow fast
implementation of the essential methods, while continuous
innovation in technologies and practices has resulted in
improvements in analytical capabilities and reduction in
development time. Examples will be discussed to
demonstrate the challenges and progress.
Hong Jiang, Scientist, Biogen
14.20 – 14.50 From Monomer Synthesis To A H10/12 Peptide-Like Helix
• Asymmetric synthesis of novel g-amino acids
• Synthesis and characterisation of foldamers
Andre Cobb, Senior Lecturer in Organic Chemistry, King’s
College London
Chromatographic Purification Of Peptides To Enable
Progress In Early Drug Discovery Projects
• Purification by chromatography is essential for delivery
of potential therapeutic agents to projects, and the
complex impurity pattern from the sequential solid-
phase synthesis of biomolecules requires optimised
chromatographic methods
• The Separation Science Laboratory at AstraZeneca in
Gothenburg has developed a strategy for purification of
peptides, and the potential of using different
chromatographic techniques will be presented
Linda Thunberg, Associate Principal Scientist,
AstraZeneca
Functional Rearrangement Of RNA-Binding Proteins
On Cancer-Related mRNAs Upon Drug Treatment
• Use of antisense oligonucleotides or aptamers for
isolation of mRNAs and bound proteins
• Cisplatin induces post-transcriptional regulation of
cancer-related mRNAs
• RNA-binding proteins modulate drug sensitivity of
cancer cells
Andre Gerber, Professor of RNA Biology, University
of Surrey
14.50 – 15.20
Early Peptide Analytics And Characterisation
Derek McMillan, Reader in Organic Chemistry, UCL
Title To Be Confirmed
Fabrizio Badalassi, Director Chemical Development,
Ferring Pharmaceuticals
Oligonucleotides Synthesis Updates
David Williams, Reader in Chemical Biology,
University of Sheffield
15.20 – 16.20 Afternoon Coffee & Refreshments, One to One Meetings, Poster Presentation Sessions
7th Annual Peptides & Oligonucleotides Congress
Day Two – 28 April 2020
Peptide Design, Synthesis, Analytical Technologies Peptide Purification, Manufacturing & Process
Development
Oligonucleotide Synthesis, Chemistry, Formulation
& Delivery, Process & Analytical Development
16.20 – 16.50 Solution Provider Presentation
For sponsorship opportunities please contact
sponsorship@oxfordglobal.co.uk
Solution Provider Presentation
For sponsorship opportunities please contact
sponsorship@oxfordglobal.co.uk
Solution Provider Presentation
For sponsorship opportunities please contact
sponsorship@oxfordglobal.co.uk
16.50 – 17.20 Genetic Validation Of Treatment Of Pain With Natural
Peptides
Justin Murray, Principal Scientist, Amgen
Peptide Impurity Control Strategies
• Summary of applicable regulations to peptide drugs
• Challenges in managing commercial supply with lack of
harmonised applicable guidelines
• Overview of peptide manufacturing technologies and
case studies for peptide impurity control
• Conclusions and future perspectives
Martin Kenworthy, Associate Principal Scientist,
AstraZeneca
The Use Of Click Chemistry To Assemble Novel
Modified DNA And RNA Constructs And On New
Methods Of DNA Synthesis
Afaf El-Sagheer, Professor, University of Oxford
17.20 – 17.50 Infinite Affinity Peptide Superglue For Empowering
Proteins And For Global Health
• SpyTag and SnoopTag are peptides allowing autocatalytic
covalent bond formation to their protein partner
• Linking enzymes or antibodies to SpyTag enables their
purification, multiplexing, irreversible anchoring, or
oligomerisation for enhanced function
• Plug-and-display decoration of virus-like particles enhances
vaccine development for viral diseases, cancer and major
global health challenges
Mark Howarth, Professor of Protein Nanotechnology,
University of Oxford
Sustainability Challenges In Peptide Synthesis And
Purification: From R&D To Production
Albert Isidro Llobet, Associate Fellow and Investigator,
GlaxoSmithKline
Structural Analysis Of Oligonucleotides
Frank Sobott, Chair in Biomolecular Mass
Spectrometry, University of Leeds
7th Annual Peptides & Oligonucleotides Congress – Pre-Dinner Roundtable Discussions
17.50 – 18.30
Table 1 – Overcoming Peptide Analytical Challenges
Table 2 – Developing Successful Peptide Therapeutics
Table 3 – Oral Delivery Of Oligonucleotides
18.30 End of Day Two & Congress Dinner
7th Annual Peptides & Oligonucleotides Congress
Day Three – 29 April 2020
7th Annual Peptides & Oligonucleotides Congress
Peptide Therapeutics
Oligonucleotide Therapeutics & Manufacturing
08.30 – 09.00 Stream Keynote Address:
Antibody-Guided Discovery Of Potent Fusion Inhibitors Of Influenza Virus
Influenza therapeutics with new targets and mechanisms of action are urgently needed to
combat potential new pandemics, emerging viruses, and constantly mutating circulating strains.
We report here on discovery and structural characterization of potent peptidic inhibitors against
influenza hemagglutinin (HA). Guided by the knowledge of the molecular interactions and the
mechanism of anti-stem broadly neutralizing antibodies (bnAbs) CR6261, CR9114 and FI6v3, we
selected and optimized molecules that effectively mimic the bnAb functionality. Our lead
compound potently neutralizes influenza A group 1 viruses by inhibiting HA-mediated fusion. Co-
crystal structures with H1 and H5 HAs reveal that the lead compound recapitulates the bnAb
hotspot interactions.
• Influenza fusion inhibitors
• Antibody-guided discovery
• doi: 10.1126/science.aan0516
Maria Van Dongen, Head External Innovation Discovery Sciences, Janssen
Stream Keynote Address:
Trends In Developing Oligo Specific CMC Understanding By Exploiting Prior Knowledge
And CMC ‘Hot Topics
There is currently no regulatory guidance specifically for the development of oligonucleotide
therapeutic agents, and as a result existing small molecule guidance is interpreted by sponsors. The
presentation will provide an overview of key CMC which have benefited from harmonization and
sharing of Prior Knowledge. The presentation will also contain examples of industry collaboration and
the future directions and prioritise in publishing data on oligo CMC ‘hot topics’.
Nigel Richardson, Head, McLean Pharma
09.00 – 09.30 Peptide Therapeutics: Novel Peptides For Novel Disease Treatments
Rami Hannoush, Principal Scientist, Genentech
MiRNA Therapeutics: From Bench To Bedside
• Non-coding RNAs play an important role in cellular regulation in health and disease and hence
could be novel targets for future medicines
• MicroRNAs are short non-coding RNAs that regulate biochemical pathways and networks of
pathways by the mechanism of RNA interference (RNAi). MicroRNA-21 has been implicated in
multiple organs as a microRNA associated with fibrotic diseases and cancer
• The presentation will summarize the opportunities and challenges of developing microRNA-based
drugs and will illustrate the successful generation of an anti-fibrotic microRNA-based therapeutic
approach by targeting microRNA-21 with an antisense oligonucleotide (anti-miR-21). This
microRNA-based drug is now in a phase 2 clinical trial for a fibrotic kidney disease called Alport
Syndrome
Ekkehard Leberer, Senior Director, Sanofi
09.30 – 10.00 Solution Provider Presentation
Solution Provider Presentation
For sponsorship opportunities please contact
sponsorship@oxfordglobal.co.uk
10.00 – 11.00 Morning Coffee & Refreshments, One to One Meetings, Poster Presentation Sessions
7th Annual Peptides & Oligonucleotides Congress
Day Three – 29 April 2020
Peptide Therapeutics Oligonucleotide Therapeutics & Manufacturing
11.00 – 11.30 Solution Provider Presentation
Leendert van den Bos, Chief Executive Officer, EnzyTag
Solution Provider Presentation
For sponsorship opportunities please contact
sponsorship@oxfordglobal.co.uk
11.30 – 12.00 Engineering (Hybrid) Peptidomimetics For Improved Pain Treatments
Steven Ballet, Professor, Departments of Chemistry and Bio-Engineering Sciences,
Free University Brussels
The Development Of saRNA Medicines Including The Use Of Medicinal Chemistry And
Drug Delivery Technologies
Matthew Catley, Research Director, MiNA Therapeutics
12.00 – 12.30 Discovery And Optimisation Of Bicycles® As A New Class Of Anti-Infective Agents
• Introduction to Bicycle Therapeutics and Bicycle peptides, a novel therapeutic modality
• Rationale for use of Bicycles as novel anti-infectives
• Summary of discovery and characterisation of Bicycle peptides against a range of bacterial
targets
Helen Harrison, Group Leader, Bicycle Therapeutics
TANGO – Targeted Augmentation Of Nuclear Gene Output For The Treatment Of Genetic
Diseases
Gene Liau, Executive Vice President and Head, Research & Preclinical Development, Stoke
Therapeutics
12.30 – 13.00 Solution Provider Presentation
For sponsorship opportunities please contact
sponsorship@oxfordglobal.co.uk
Solution Provider Presentation
For sponsorship opportunities please contact
sponsorship@oxfordglobal.co.uk
13.00 – 14.00 Lunch, One to One Meetings x3, Poster Presentation Sessions
14.00 – 14.30
Aelin Therapeutics - Harnessing the power of protein aggregation
• Pept-inTM: a new modality in drug development: the functional inhibition of proteins via induction
of aggregation
• Pept-insTM can treat antibiotic-resistant Gram-negative bacterial infections by inducing toxic
protein aggregation within bacterial cells
• Aelin Therapeutics is developing Pept-insTM against high-value undruggable human targets in other disease fields such as oncology
Victor Terrier, Scientist, Aelin Therapeutics
The Yin & Yang Of Sulfur
Phosphorothioates have been introduced into oligonucleotides even before the advent of ASOs and
turned out to be a key component in most of the clinically validated antisense oligonucleotide drugs.
Here we report our latest observations of backbone modified ASOs with a particular focus on
thiophosphate modifications, including stereo-defined internucleoside linkages.
Konrad Bleicher, Group Leader, RNA Therapeutics, F.Hoffmann – La Roche
7th Annual Peptides & Oligonucleotides Congress
Day Three – 29 April 2020
Peptide Therapeutics
Oligonucleotide Therapeutics & Manufacturing
15.30 – 16.00 Afternoon Coffee & Refreshments, Poster Presentation Sessions
14.30 – 15.00 Identification And Aptimization Of A Nectin-4 Selective Bicycle For Targeted Delivery
Of Cytotoxic Payloads
• The Bicycle® phage display platform was used to identify Bicycles® which bind selectively
to Nectin-4
• Nectin-4 is a cell adhesion molecule with a restricted distribution in normal tissues, but over
expressed in multiple tumour types
• A lead Bicycle® was chemically optimised to enhance affinity, proteolytic stability and
solubility
• The chemically optimised Bicycle was incorporated into a Bicycle Toxin Conjugate (BTC),
whereby it was conjugated via a cleavable linker to the antimitotic toxin monomethyl
auristatin E (MMAE), giving BT8009
• The pharmacokinetic profile of BT8009 enables a rapid attainment of high levels of MMAE
in tumor with low systemic exposure, thereby sparing healthy tissue
• BT8009 shows excellent efficacy in xenograft models expressing Nectin-4
Gemma Mudd, Senior Scientist, Bicycle Therapeutics
Developing First In Class RNA Oligonucleotide In Patients With Liver Cancer
Nagy Habib, Professor and Head of the Surgery Hammersmith Campus, Imperial College
London
15.00 – 15.30 An Integrated Platform For The Discovery Of Intrinsically Membrane Permeable
Macrocycles Targeting The RXL-Binding Domain Of Cyclin A / Cdk2 And Cyclin E /Cdk2
For The Treatment Of Small Cell Lung Cancer
• Circle has established a platform approach to macrocycle therapeutic discovery emphasizing
intrinsic permeability as a key step in the design workflow
• The platform integrates semi-automated solid phase synthesis of peptide/peptoid hybrids
and both structure-based and ligand-based affinity design methods to target key protein-
protein interactions in oncology
David Earp, President, Chief Executive Officer, Circle Pharma
Lipophilic And Cationic LNA-Based Antisense Oligonucleotides
• Improved pharmacokinetics
• Novel opportunities
• Innovative ASO designs
Jesper Wengel, Professor of Nucleic Acid Center, University of Southern Denmark
16.00 – 16.30 Peptide Therapeutics Application Within Infectious Diseases
Li Li, Principal Scientist, Merck
Nanostar Sieving For Liquid Phase Synthesis Of Oligonucleotides
• More than 130 oligonucleotide drugs are in trials and many of these for mainstream medical
needs. This is creating an imperative to develop scalable technology to manufacturfe oligos at the
multi-ton scale
• Nanostar seiving uses iterative synthesis via protecting groups coupled to nanomembranes to
sieve the growing oligos from reaction debris, so that the whole synthesis is carried out in the
liquid phase
• Oligos produced by nanostar sieving are more than 90%pure before chromatograhpy; the
process can be scaled to any bacth size; and because it is liquid phase process controls can be
used to ensure quality
Andrew Livingston, Professor of Chemical Engineering, Queen Mary, University of London
7th Annual Peptides & Oligonucleotides Congress
Day Three – 29 April 2020
Peptide Therapeutics
Oligonucleotide Therapeutics & Manufacturing
16.30 – 17.00 Targeted, Controlled And Responsive Therapeutic Delivery Through The Design Of
Self-Assembling Peptide Hydrogels
• Design rules for engineering responsive peptide hydrogels
• Targeting endometriosis with sprayable peptide hydrogels
• Delivery of therapeutics to solid tumors
• Mucoadhesive hydrogels to prolong therapeutic efficacy
Aline Miller, Professor, University of Manchester
Strategies For Identity Testing OF Oligonucleotide Therapeutics
Nadim Akhtar, Principal Scientist Characterisation & Control Strategy, AstraZeneca
17.00 – 17.30 Potential Applications For Immune-Boosting Peptides
• Global unmet needs exist in the fields of cancer immunotherapy, overcoming deleterious
effects of UV irradiation on the skin, development of non-opioid analgesics and drug
addiction
• Peptides that boost the immune system may offer therapeutic options that complement
existing strategies to address the above challenges
Michael Agrez, Chief Executive Officer, InterK Peptide Therapeutics
Evaluating Oligonucleotides As Personalised Medicines
Haiyan Zhou, Principal Investigator and Group Leader, University College London
17.30 – 18.00 Peptide Modalities: From Bench To Humans
• Pulmonary diseases
• Opitcal Imaging chemical tools (peptides)
• Evaluation of drug target engagements and effects in first in-human exploratory study
Sunay Chankeshwara, Associate Principal Scientist, Senior Expert Peptide Chemistry,
AstraZeneca
The Oligonucleotide Agent BC 007 For Neutralization Of Functionally Active Pathogenic
Autoantibodies Directed Against ß 1-Adrenoceptors In Heart Failure Patients – First Phase
II Data
• Functionally active pathogenic autoantibodies (fAAb) against G-protein coupled receptors (fGPCR-
AAbs) are triggers and sustainers of a variety of diseases, mostly affecting the heart and vascular
system as e.g. heart failure (HF; here autoantibodies against the β1-adrenoceptor (fβ1-AAb)) or
pulmonary arterial hypertension (here fAAB against the endothelin ETA-receptor) and sinus
bradycardia (fAAB against the muscarinic M2 receptor)
• As already seen in elderly healthy but fGPCR-AAb positive volunteers in Phase-I, BC 007
neutralizes these fAAbs in patients with progressed HF as well
• Besides this demonstrated mode of action, Phase-I safety tests showed an excellent tolerability,
no clinically relevant side effects. Transient elevated aPTT to subclinical values, paralleling the
infusion, were observed in some subjects
• A two-arm randomized, open-label Phase-IIa study, investigating the temporal persistence of the
fβ1-AAb neutralization, safety and pharmacokinetic in chronic HF patients with reduced ejection
fraction, including twenty β1-AAb positive HF patients and ten positive patients who serve as
controls, is currently running. First efficacy data will be presented
Annekathrin Haberland, Director, Regulatory Affairs, Berlin Cures
7th Annual Peptides & Oligonucleotides Congress
Day Three – 29 April 2020
Peptide Therapeutics
18.00 – 18.30 Oral Administration Of Nanofitins For Treatment Of Mucosal Inflammation – A Dual
Targeting Approach
• Nanotifins are small, hyperstable, custom affinity proteins that can be combined to achieve
multispecificity
• Stability includes strong gastric resistance and local activity in the GI tract
• Ongoing development against mucosal targets will be shared
Olivier Kitten, Founder, Chief Executive Officer, Affilogic
De-Orphanizing Primary T Cells Using DNA-Encoded Peptide-MHC Libraries On Beads
Graham Ogg, Founder, Orbit Discovery
18.30 End of Conference
I cannot attend but would like to purchase access to the following:
Access to the online conference presentations £499 plus VAT VAT is charged at 20% on the attendance fees for all delegates. VAT is also charged on online and paper copy documentation and promotional literature distribution for all UK customers and for those EU customers not supplying a registration number for their own country here.
Biologics Series
13th Annual Proteins & Antibodies Congress | 7th Annual Peptides & Oligonucleotides Congress 2nd Annual Bispecifics in Discovery & Development Congress
27 - 29 April 2020, Novotel London West, London, UK www.oxfordglobal.co.uk/biologics-series/
HOW TO REGISTER: FAX your booking form to +44(0)1865 689120 | PHONE on +44(0)1865 248455 | EMAIL: marketing@oxfordglobal.co.uk
Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate:
Delegate Booking Fee The Delegate Booking Fee includes: lunches and refreshments throughout the Series, presentations and panel sessions, scheduled one-to-one meetings and networking/social events, Series and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser.
An admin surcharge of £50 plus VAT will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online. Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility.
Acceptance of a Complimentary Pass If you are offered a free delegate pass and you are unable to attend the Series, you may nominate a substitute of equal standing (in terms of business and financial responsibility). A substitute delegate must be nominated within a week of cancellation and must be approved by the Organiser in ad-vance in order to avoid a non-attendance charge of £200 plus VAT being applied. Your complimentary delegate place is not officially confirmed until we have had chance to check that you qualify for the complimentary pass. Please do not make any travel arrangements before we have confirmed acceptance of your application. We will not be liable for any expenses incurred.
Delegate Registration Form Each Delegate must complete the online delegate registration form issued by the Organiser on receipt of the Delegate Booking Form. This information will only be used for the organisation of the Series, for material produced for Delegates and Sponsors and to facilitate the networking sessions.
Cancellation and Curtailment If a Registered Delegate is unable to attend the Series, he/she may nominate a substitute of equal standing within their Company. A substitute delegate must be nominated within a week of cancellation and must be approved by the Organiser in advance in order to avoid cancellation charges being applied. Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation.
More than 6 months prior 35% cancellation fee / 65% refund Between 6 and 3 months prior 75% cancellation fee / 25% refund Less than 3 months prior to the event Full cancellation fee / No refund
Data Protection The data controller is the organiser (Oxford Global Marketing Ltd). Registration details will be retained and used in accordance with our privacy policy. Your information may be shared with selected partners and contractors, solely for the for the purposes of the event. Please note: If you attend an event then a sponsor or exhibitor may scan your badge. This is the equivalent to handing over your business card. Should you allow your badge to be scanned then Oxford Global will share your Personal Information with the relevant sponsor or exhibitor. If you register for a sponsor-led workshop or session (by actively selecting this option at the point of registration or allowing your badge to be scanned on entry to the session), you are agreeing to share your personal information with the named sponsor
Miscellaneous The Organiser will determine the scope and content of Series events, seminars, workshops and activities throughout the Series. The Organiser reserves the right to cancel the Series without liability to Delegate’s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Series, the Organiser reserves the right to transfer this Booking to another Series within the same sector to be held within twelve months. Should another Series in the same sector not be available within this period, the Booking Fee will be refunded. For promotional purposes, there may be professional photography and video production taking place during the Series. Delegates who do not wish to be filmed or recorded should advise the organisers by email to operations@oxfordglobal.co.uk prior to the event. These terms and conditions are binding upon the delegate submitting a registration form.
If you have any further queries please call the marketing team on +44(0)1865 248455 or email marketing@oxfordglobal.co.uk
Delegate Details
Terms & Conditions of Booking
I agree to the above Terms and Conditions
Registration Fees
Documentation
How to Pay (choose one of the following payment options)
I would like to attend: (Please tick as appropriate) Industry Delegates (Biopharma, Pharma or Biotech Companies) 2-day pass £899 plus VAT 1-day pass £599 plus VAT Day 1 (with complimentary access to the pre-event workshop) Day 2 Day 3 Academic Delegates 2-day pass £520 plus VAT 1-day pass £320 plus VAT Day 1 (with complimentary access to the pre-event workshop) Day 2 Day 3 Vendor Delegates (CROs, Consultants, Technology and Service Providers) Series Only £1750 plus VAT Poster Presentation £250 plus VAT PROMOTIONAL LITERATURE DISTRIBUTION Distribution of your company’s promotional literature to all Series attendees £999 plus VAT
Number of delegates:
Industry del(s) Academic dels(s) Vendor dels(s)
Special Offer: 3 for 2 Offer is only valid on the Series and for those registering at Industry or Academic rates
Please choose one of the following payment options:
CREDIT CARD:
An Oxford Global representative will contact you directly following return of contract / booking form to process card payment. If payment will be made by a colleague within your company, please complete the following;
Card Payment Contact Name: ___________________________________
Phone Number: _________________________________________________ INVOICE:
Invoice Address (if different from above) ________________________
__________________________________________________________________
__________________________________________________________________
*Please note there is a £50 plus VAT handling charge for payment via invoice
Please complete fully and clearly. Please photocopy for additional delegates. Please tick which event(s) in the Series you are interested in: Proteins & Antibodies Congress Bispecifics Congress Peptides & Oligonucleotides Congress Title:_____ Forename:__________________ Surname:__________________ Job Title:___________________________________________________________ Company/Organisation:___________________________________________ Email:_____________________________________________________________ Address:___________________________________________________________ Postcode: ________________________ Country: _________________________ Direct Telephone _______________ Direct Fax: ________________ Mobile: ________________________ Switchboard: _____________ Signature: ______________________ Date: ___________________________